Clinicians with obligations to patients and to organizations often assess patients in law enforcement for both therapeutic and nontherapeutic purposes.
AMA J Ethics. 2022; 24(2):E111-119. doi:
10.1001/amajethics.2022.111.
Carlos Martinez, MPH, Lauren Carruth, PhD, Hannah Janeway, MD, Lahra Smith, PhD, Katharine M. Donato, PhD, Carlos Piñones-Rivera, PhD, James Quesada, PhD, and Seth M. Holmes, MD, PhD
Transnational violence has been created by international policy, militaristic interventions, and multinational organizational administration of border operations.
AMA J Ethics. 2022; 24(4):E275-282. doi:
10.1001/amajethics.2022.275.
José G. Pérez Ramos, PhD, MPH, Adriana Garriga-López, PhD, and Carlos E. Rodríguez-Díaz, PhD, MPH
Hurricane María, earthquakes, the COVID-19 pandemic, and relentless privatization and fragmentation of the health care system have led to very poor health outcomes.
AMA J Ethics. 2022; 24(4):E305-312. doi:
10.1001/amajethics.2022.305.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021; 23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Deborah M. Eng, MS, MA and Scott J. Schweikart, JD, MBE
A just culture perspective suggests that punitive responses to those who err should be reserved for those who have willfully and irremediably caused harm.
AMA J Ethics. 2020; 22(9):E779-783. doi:
10.1001/amajethics.2020.779.